TuHURA Biosciences (NASDAQ:HURA) Lowered to “Sell” Rating by Wall Street Zen

TuHURA Biosciences (NASDAQ:HURA) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Wednesday, October 8th. Maxim Group lowered their price objective on TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $10.33.

TuHURA Biosciences Price Performance

Shares of NASDAQ:HURA opened at $1.03 on Friday. The business has a fifty day moving average price of $2.14 and a 200-day moving average price of $2.47. The company has a market capitalization of $52.54 million, a PE ratio of -2.05 and a beta of -0.03. TuHURA Biosciences has a 1-year low of $0.97 and a 1-year high of $5.61.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01.

Institutional Investors Weigh In On TuHURA Biosciences

A number of large investors have recently added to or reduced their stakes in the stock. Invst LLC bought a new position in shares of TuHURA Biosciences in the first quarter worth about $61,000. Invesco Ltd. purchased a new stake in TuHURA Biosciences in the 2nd quarter worth approximately $30,000. JPMorgan Chase & Co. bought a new stake in TuHURA Biosciences during the 2nd quarter worth approximately $27,000. Virtu Financial LLC purchased a new position in TuHURA Biosciences during the third quarter valued at approximately $26,000. Finally, SG Americas Securities LLC bought a new position in shares of TuHURA Biosciences in the third quarter worth approximately $41,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.